BBP - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Products ETF (BBP)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in the most recent month, indicating positive momentum in its holdings.
Leading Biotech Winners in Top Holdings
Several of the largest positions, such as ImmunityBio, Day One Biopharmaceuticals, and Moderna, have delivered strong year-to-date results that support the fund’s overall performance.
Moderate Expense Ratio
The fund’s expense ratio is moderate for a specialized biotech strategy, helping investors keep more of their returns compared with many actively managed funds.
Negative Factors
Heavy Sector Concentration
Almost all assets are invested in health care and biotech, which increases risk if this single sector experiences a downturn.
Limited Geographic Diversification
With nearly all exposure in U.S. companies, the ETF offers little geographic diversification and is highly tied to the U.S. market and regulatory environment.
High Industry Volatility Risk
Biotech stocks can be very sensitive to drug trial results and regulatory news, which may lead to sharp swings in the ETF’s price.
BBP vs. SPDR S&P 500 ETF (SPY)
AUM59.29M
RegionNorth America
Expense Ratio0.34%
Beta0.91
IssuerVirtus
Inception DateDec 17, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedLifeSci Biotechnology Products Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,203
30 Day Avg. Volume6,810
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
129.57Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering60
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBP Summary
The Virtus LifeSci Biotech Products ETF (BBP) tracks the LifeSci Biotechnology Products Index and focuses on U.S. biotechnology companies developing and selling new drugs and medical treatments. It holds a mix of well-known names like Moderna and Novavax, along with smaller, fast-growing biotech firms. Someone might invest in BBP to seek long-term growth from medical breakthroughs and to get diversified exposure to many biotech stocks in a single fund. However, this ETF is heavily tied to the biotech sector, so its price can be very volatile and may swing sharply with drug trial news and regulation changes.
How much will it cost me?The Virtus LifeSci Biotech Products ETF (BBP) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like biotechnology that requires more research and expertise.
What would affect this ETF?The Virtus LifeSci Biotech Products ETF (BBP) could benefit from advancements in biotechnology and increased demand for innovative medical treatments, particularly in the U.S., where it is focused. However, it may face challenges from regulatory hurdles, high research and development costs, or broader economic downturns that could impact funding and growth in the biotech sector.
BBP Top 10 Holdings
BBP is a pure-play U.S. biotech fund, and its story is all about high-risk, high-reward drug developers. Apellis has been a bright spot lately, helping pull the fund higher as enthusiasm builds around its pipeline. Day One, Iovance, and Roivant are also rising, giving the portfolio a lift as investors warm to their growth narratives despite ongoing losses. On the flip side, ImmunityBio has been wobbly and Novavax is clearly lagging, acting like a weight on returns. Overall, performance is driven by a concentrated group of mid-cap biotech names rather than broad market trends.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ImmunityBio | 4.98% | $2.92M | $7.65B | 177.19% | 48 Neutral | |
| Moderna | 2.67% | $1.56M | $20.12B | 77.35% | 59 Neutral | |
| Apellis Pharmaceuticals | 2.62% | $1.54M | $5.23B | 128.01% | 50 Neutral | |
| Iovance Biotherapeutics | 2.51% | $1.48M | $1.54B | -4.99% | 50 Neutral | |
| Mirum Pharmaceuticals | 2.29% | $1.35M | $5.52B | 123.87% | 56 Neutral | |
| Ligand Pharma | 2.06% | $1.21M | $4.61B | 122.07% | 60 Neutral | |
| Axsome Therapeutics | 2.04% | $1.20M | $9.51B | 74.75% | 57 Neutral | |
| Roivant Sciences | 2.03% | $1.19M | $19.62B | 148.88% | 58 Neutral | |
| Zai Lab | 1.99% | $1.17M | $2.54B | -32.53% | 48 Neutral | |
| Novavax | 1.98% | $1.16M | $1.34B | 20.36% | 47 Neutral |
BBP Technical Analysis
Positive
―
Price Trends
83.73
Positive
82.37
Positive
76.36
Positive
Market Momentum
0.33
Positive
51.94
Neutral
26.89
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 85.33, equal to the 50-day MA of 83.73, and equal to the 200-day MA of 76.36, indicating a neutral trend. The MACD of 0.33 indicates Positive momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 26.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBP.
BBP Peer Comparison
Comparison Results
Performance Comparison
BBP
Virtus LifeSci Biotech Products ETF
84.97
27.14
46.93%
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
XHS
SPDR S&P Health Care Services ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents